Aldeyra Therapeutics Reshuffles Pipeline, Discontinues ADX-629 Development
Aldeyra Therapeutics, a biopharmaceutical company focusing on novel therapies for immune-mediated diseases, has announced significant changes to its drug development pipeline. The company's decision to halt clinical development of one asset and reprioritize others comes in response to recent clinical data and strategic assessments.
ADX-629 Development Halted
Despite reporting significant improvements in a phase 2 liver-disease trial, Aldeyra has decided to discontinue clinical development of ADX-629. The company will allow an ongoing investigator-sponsored trial in Sjögren-Larsson syndrome to continue but has chosen not to pursue further human studies for this molecule. This decision follows the earlier deprioritization of ADX-629 in chronic cough and idiopathic nephrotic syndrome in early 2024.
Pipeline Reprioritization in Key Therapeutic Areas
Metabolic Inflammation
Aldeyra has shifted its focus in metabolic inflammation, including obesity, from ADX-743 to ADX-248. This change was prompted by phase 1 data suggesting high levels of exposure with once-daily oral dosing of ADX-248, making it a more promising candidate for further development.
Dry Age-Related Macular Degeneration
In the dry AMD program, the company has pivoted from ADX-631 to ADX-246. This decision was based on results from an animal model of the condition. Aldeyra plans to file an application to initiate clinical trials of ADX-246 in 2026.
Financial Outlook and Future Prospects
Following these pipeline adjustments, Aldeyra projects that its cash runway will extend into the second half of 2027. The company's near-term focus is on the potential approval of reproxalap for dry eye disease, with an FDA decision expected by the end of 2025. If approved, AbbVie will have a 10-business-day window to exercise its option on the asset.
These strategic moves reflect Aldeyra's commitment to optimizing its pipeline based on emerging data and market potential. The company continues to concentrate on developing novel therapies for dermatologic, metabolic, and retinal immune-mediated diseases, with ADX-248 and ADX-246 now at the forefront of its clinical programs.
References
- Aldeyra shuffles RASP pack, dropping and swapping assets in response to data
Aldeyra Therapeutics has shaken up its drug development pipeline, stopping work on one asset in the wake of phase 2 data and swapping out two other molecules in response to recent results.
Explore Further
What are the primary reasons Aldeyra Therapeutics decided to discontinue the development of ADX-629 despite its phase 2 improvements in liver disease trials?
What differentiates ADX-248 from ADX-743 in terms of metabolic inflammation treatment potential based on phase 1 clinical data?
How does Aldeyra plan to position ADX-246 in the competitive landscape of treatments for dry age-related macular degeneration?
What factors could influence AbbVie’s decision to exercise its option on reproxalap for dry eye disease following FDA approval?
What are the estimated market sizes for the key therapeutic areas Aldeyra is focusing on, such as retinal immune-mediated diseases and metabolic inflammation?